Company profile
Beta Bionics, Inc.
NASDAQ: BBNX · Healthcare · Medical - Devices
#351 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
58CFH 61DQ 53GM —SS 55
v0.1 · 55/100 weight · provisional
↑ filing timeliness, Altman-Z · ↓ listing tenure, disclosure history
Methodology →Revenue TTM
$119.0M
Rev growth YoY (TTM)
+52.5%
Net income (FY)
-$73.2M
Employees
422
as of 2026-08-11
Market cap
$737.8M
as of 2026-08-11
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$100.3M$100.3M2025
Net income-$73.2M-$73.2M2025
Operating income-$71.7M-$71.7M2025
Total assets$328.7M$328.7M2025
Liabilities$41.1M$41.1M2025
Equity$287.6M$287.6M2025
Revenue trend
FY2024 – FY2025 · USD
FY24
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Beta Bionics, Inc.’s revenue?
Beta Bionics, Inc. booked $100.3M in FY2025 revenue, growing 54% year over year — faster than most Healthcare companies we track, at a -73.0% net margin.
Peers · Healthcare
Sutro Biopharma, Inc.47DViewRay, Inc.——StateHouse Holdings Inc.——NeuroPace, Inc.53DMedexus Pharmaceuticals Inc.64CButterfly Network, Inc.62CNeighbors
Orange →Key facts
CEOSean T. Saint
SectorHealthcare
IndustryMedical - Devices
HeadquartersIrvine, CA
ExchangeNASDAQ: BBNX
Employees422
IPO date2025-01-30
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.